SCHEMBL5776413

SCHEMBL5776413

Cc1ccc(S(=O)(=O)N2CCN(c3ccc(C(F)(F)F)cn3)C(C)(C)C2)cc1CC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
F13A1 P00488 1/20 0.41
TGM2 P21980 1/20 0.41
TGM1 P22735 1/20 0.41
PKM P14618 2/20 0.41
CXCR3 P49682 4/20 0.40
GAA P10253 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GCK P35557 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
CCR6 P51684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5487074 0.86 KDM4E (0.59) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL6348135 0.84 KDM4E (0.66) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL5480564 0.83 CXCR3 (0.48) KDM4EF13A1TGM2TGM1CXCR3
SCHEMBL6356889 0.83 CXCR3 (0.48) KDM4EF13A1TGM2TGM1CXCR3
SCHEMBL5748075 0.83 KDM4E (0.47) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL6357386 0.83 CXCR3 (0.48) KDM4EF13A1TGM2TGM1CXCR3
SCHEMBL27754624 0.82 GCKR (0.45) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL5747872 0.82 GCKR (0.45) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL5795980 0.82 CXCR3 (0.48) KDM4EL3MBTL1F13A1TGM2TGM1
SCHEMBL6346422 0.80 F13A1 (0.41) KDM4EL3MBTL1F13A1TGM2TGM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD KDM4E 3692/4885L3MBTL1 4277/4885F13A1 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.